Ingmar Hoerr, PhD, MBA, Co-Founder / Chairman of the Supervisory Board co-founded CureVac in 2000 in Tübingen. His entrepreneurship was motivated by a surprising discovery during his doctoral research. Experiments conducted for this research showed that the mRNA molecule class can be injected into tissue directly and is capable of expressing genes into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed. From this key discovery, he built up a company in his role as CEO that was the first ever to treat a human subject with an mRNA drug and that is now a leading German “unicorn” in the research and development of mRNA-based drugs. Since its inception, CureVac has received approximately $330 million (€300 million) in equity investments. The company is valuated at $2 billion.
Ingmar Hoerr received his PhD from the University of Tuebingen and his MBA from Danube University, Krems, Austria. He currently advises the European Commission as member of the High Level Group of Innovators in developing an European Innovation Council and is juror of the founder prize Weconomy.